TheStreet upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a d rating to a c- rating in a report published on Monday, March 19th.
A number of other brokerages have also commented on NTLA. BidaskClub lowered shares of Intellia Therapeutics from a strong-buy rating to a buy rating in a report on Wednesday, March 21st. Oppenheimer restated a hold rating on shares of Intellia Therapeutics in a report on Tuesday, December 12th. Wedbush restated an outperform rating and set a $36.00 price objective on shares of Intellia Therapeutics in a report on Thursday, March 15th. Leerink Swann restated an outperform rating on shares of Intellia Therapeutics in a report on Wednesday, March 14th. Finally, JMP Securities initiated coverage on shares of Intellia Therapeutics in a report on Thursday, March 8th. They set an outperform rating on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $34.83.
Shares of NASDAQ NTLA traded up $0.31 during midday trading on Monday, reaching $22.25. 751,792 shares of the stock were exchanged, compared to its average volume of 1,167,221. The stock has a market cap of $948.63, a price-to-earnings ratio of -11.84 and a beta of 2.83. Intellia Therapeutics has a 12 month low of $11.15 and a 12 month high of $35.99.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Wednesday, March 14th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.16). The firm had revenue of $6.70 million for the quarter, compared to the consensus estimate of $8.84 million. Intellia Therapeutics had a negative return on equity of 31.27% and a negative net margin of 258.62%. The company’s revenue for the quarter was up 19.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.31) earnings per share. analysts forecast that Intellia Therapeutics will post -2.27 EPS for the current fiscal year.
In other Intellia Therapeutics news, Director Jean Francois Formela sold 39,245 shares of Intellia Therapeutics stock in a transaction on Tuesday, March 20th. The shares were sold at an average price of $23.87, for a total value of $936,778.15. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of Intellia Therapeutics stock in a transaction on Monday, January 29th. The shares were sold at an average price of $26.78, for a total transaction of $14,746,273.10. The disclosure for this sale can be found here. 12.80% of the stock is currently owned by insiders.
A number of hedge funds have recently modified their holdings of the business. Farallon Capital Management LLC acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth about $21,911,000. ARK Investment Management LLC increased its stake in shares of Intellia Therapeutics by 269.2% during the 4th quarter. ARK Investment Management LLC now owns 1,375,149 shares of the company’s stock worth $26,430,000 after purchasing an additional 1,002,671 shares during the last quarter. GMT Capital Corp acquired a new position in shares of Intellia Therapeutics during the 3rd quarter worth about $8,214,000. Shellback Capital LP acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth about $2,343,000. Finally, Capital Advisors Inc. OK acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth about $1,946,000. Hedge funds and other institutional investors own 57.10% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Macon Daily and is the sole property of of Macon Daily. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://macondaily.com/2018/04/12/intellia-therapeutics-ntla-upgraded-by-thestreet-to-c-updated-updated-updated-updated.html.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.